{"id":57014,"date":"2026-02-12T22:33:30","date_gmt":"2026-02-12T14:33:30","guid":{"rendered":"https:\/\/flcube.com\/?p=57014"},"modified":"2026-02-12T22:33:32","modified_gmt":"2026-02-12T14:33:32","slug":"novartis-secures-long-term-actinium-225-supply-from-niowave-for-radioligand-therapy-expansion","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=57014","title":{"rendered":"Novartis Secures Long-Term Actinium-225 Supply from Niowave for Radioligand Therapy Expansion"},"content":{"rendered":"\n<p><strong>Novartis AG<\/strong> (<strong><a href=\"https:\/\/www.google.com\/finance\/quote\/NVS:NYSE\">NYSE:\u202fNVS<\/a><\/strong>) has entered a <strong>long-term supply agreement<\/strong> with <strong>Niowave Inc.<\/strong>, a <strong>US-based isotope production company<\/strong>, securing <strong>scalable access to Actinium-225 (Ac-225)<\/strong>\u2014a <strong>critical alpha-emitting isotope<\/strong> for <strong>radioligand therapies (RLT)<\/strong>. The deal addresses the <strong>severe global supply constraint<\/strong> of Ac-225, enabling <strong>Novartis to expand its industry-leading radiopharmaceutical portfolio<\/strong> beyond <strong>Lutathera and Pluvicto<\/strong> into <strong>next-generation alpha-targeted therapies<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-transaction-overview\">Transaction Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Element<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Pharma Partner<\/strong><\/td><td>Novartis AG (NYSE:\u202fNVS)<\/td><\/tr><tr><td><strong>Supplier<\/strong><\/td><td>Niowave Inc. (US-based isotope technology company)<\/td><\/tr><tr><td><strong>Commodity<\/strong><\/td><td>Actinium-225 (Ac-225)<\/td><\/tr><tr><td><strong>Deal Structure<\/strong><\/td><td><strong>Long-term supply agreement<\/strong><\/td><\/tr><tr><td><strong>Strategic Purpose<\/strong><\/td><td>Scalable Ac-225 supply for radioligand therapy (RLT) pipeline<\/td><\/tr><tr><td><strong>Technology<\/strong><\/td><td>Niowave <strong>superconducting linear accelerator<\/strong> + advanced radiochemistry<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-actinium-225-strategic-value\">Actinium-225 Strategic Value<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Property<\/th><th>Ac-225 Specification<\/th><th>Therapeutic Advantage<\/th><\/tr><\/thead><tbody><tr><td><strong>Emission Type<\/strong><\/td><td><strong>High-energy alpha particles<\/strong><\/td><td><strong>Precision cell killing<\/strong> with <strong>minimal surrounding tissue damage<\/strong> (high linear energy transfer)<\/td><\/tr><tr><td><strong>Range<\/strong><\/td><td>50-100 micrometers<\/td><td><strong>Tumor-specific destruction<\/strong>; sparing of adjacent healthy tissue<\/td><\/tr><tr><td><strong>Clinical Potential<\/strong><\/td><td><strong>Next-generation radioligand therapies<\/strong><\/td><td><strong>Overcoming beta-emitter limitations<\/strong> (Lutathera, Pluvicto) in <strong>resistant micrometastases<\/strong><\/td><\/tr><tr><td><strong>Supply Constraint<\/strong><\/td><td><strong>Global shortage<\/strong>; historically derived from <strong>thorium-229 decay<\/strong> or <strong>cyclotron production<\/strong><\/td><td><strong>Niowave&#8217;s accelerator technology<\/strong> enables <strong>sustainable, scalable manufacturing<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-novartis-radioligand-therapy-portfolio\">Novartis Radioligand Therapy Portfolio<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Product<\/th><th>Isotope<\/th><th>Status<\/th><th>Indication<\/th><\/tr><\/thead><tbody><tr><td><strong>Lutathera<\/strong><\/td><td>Lutetium-177 (beta-emitter)<\/td><td>Approved<\/td><td>GEP-NETs (gastroenteropancreatic neuroendocrine tumors)<\/td><\/tr><tr><td><strong>Pluvicto<\/strong><\/td><td>Lutetium-177 (beta-emitter)<\/td><td>Approved<\/td><td>PSMA-positive metastatic castration-resistant prostate cancer (mCRPC)<\/td><\/tr><tr><td><strong>Next-Gen RLT<\/strong><\/td><td><strong>Actinium-225 (alpha-emitter)<\/strong><\/td><td>Development<\/td><td><strong>Solid tumors, hematologic malignancies<\/strong> (AML, multiple myeloma)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Ac-225 Pipeline:<\/strong> Novartis advancing <strong>alpha-emitting radioligands<\/strong> for <strong>tumors resistant to beta-therapy<\/strong>; <strong>supply security<\/strong> critical for <strong>clinical trial execution<\/strong> and <strong>commercial scalability<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-niowave-technology-amp-competitive-positioning\">Niowave Technology &amp; Competitive Positioning<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Capability<\/th><th>Description<\/th><th>Strategic Differentiation<\/th><\/tr><\/thead><tbody><tr><td><strong>Superconducting Linear Accelerator<\/strong><\/td><td><strong>High-efficiency Ac-225 production<\/strong><\/td><td><strong>Scalable vs. reactor-derived<\/strong>; <strong>not dependent on legacy thorium supply chain<\/strong><\/td><\/tr><tr><td><strong>Advanced Radiochemistry<\/strong><\/td><td><strong>GMP-compliant isotope processing<\/strong><\/td><td><strong>Pharmaceutical-grade purity<\/strong>; <strong>regulatory-ready for human use<\/strong><\/td><\/tr><tr><td><strong>US Domestic Production<\/strong><\/td><td><strong>Lansing, Michigan facility<\/strong><\/td><td><strong>Supply chain security<\/strong>; <strong>reduced geopolitical risk<\/strong> vs. foreign isotope sources<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-industry-impact\">Market Context &amp; Industry Impact<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Strategic Analysis<\/th><\/tr><\/thead><tbody><tr><td><strong>Radioligand Therapy Market<\/strong><\/td><td><strong>$5+ billion by 2030<\/strong>; <strong>alpha-emitters<\/strong> represent <strong>next wave<\/strong> after <strong>Lu-177 beta-emitter establishment<\/strong><\/td><\/tr><tr><td><strong>Supply Bottleneck<\/strong><\/td><td><strong>Ac-225 shortage<\/strong> has <strong>delayed clinical trials<\/strong> and <strong>limited patient access<\/strong>; <strong>Niowave deal de-risks Novartis pipeline<\/strong><\/td><\/tr><tr><td><strong>Competitive Landscape<\/strong><\/td><td><strong>Bayer, AstraZeneca, Telix<\/strong> pursuing alpha-therapies; <strong>Novartis supply advantage<\/strong> via <strong>Niowave partnership<\/strong><\/td><\/tr><tr><td><strong>Theranostics Integration<\/strong><\/td><td><strong>Ac-225 therapy + diagnostic pairing<\/strong> (alpha-PET) enables <strong>precision patient selection<\/strong> and <strong>treatment monitoring<\/strong><\/td><\/tr><tr><td><strong>Manufacturing Moat<\/strong><\/td><td><strong>Reliable Ac-225 supply<\/strong> creates <strong>competitive barrier<\/strong> for <strong>latecomers<\/strong> to alpha-RLT market<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding Novartis Actinium-225 radioligand therapy development, Niowave production scalability, and alpha-emitter market expansion. Actual results may differ due to radiochemistry manufacturing challenges, regulatory requirements for alpha-emitter therapeutics, and competitive dynamics in radiopharmaceutical supply chain.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Novartis AG (NYSE:\u202fNVS) has entered a long-term supply agreement with Niowave Inc., a US-based isotope&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[16,4613,140,865],"class_list":["post-57014","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-cancer","tag-niowave","tag-novartis","tag-nyse-nvs"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Novartis Secures Long-Term Actinium-225 Supply from Niowave for Radioligand Therapy Expansion - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Novartis AG (NYSE:\u202fNVS) has entered a long-term supply agreement with Niowave Inc., a US-based isotope production company, securing scalable access to Actinium-225 (Ac-225)\u2014a critical alpha-emitting isotope for radioligand therapies (RLT). The deal addresses the severe global supply constraint of Ac-225, enabling Novartis to expand its industry-leading radiopharmaceutical portfolio beyond Lutathera and Pluvicto into next-generation alpha-targeted therapies.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=57014\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novartis Secures Long-Term Actinium-225 Supply from Niowave for Radioligand Therapy Expansion\" \/>\n<meta property=\"og:description\" content=\"Novartis AG (NYSE:\u202fNVS) has entered a long-term supply agreement with Niowave Inc., a US-based isotope production company, securing scalable access to Actinium-225 (Ac-225)\u2014a critical alpha-emitting isotope for radioligand therapies (RLT). The deal addresses the severe global supply constraint of Ac-225, enabling Novartis to expand its industry-leading radiopharmaceutical portfolio beyond Lutathera and Pluvicto into next-generation alpha-targeted therapies.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=57014\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-12T14:33:30+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-12T14:33:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57014#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57014\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Novartis Secures Long-Term Actinium-225 Supply from Niowave for Radioligand Therapy Expansion\",\"datePublished\":\"2026-02-12T14:33:30+00:00\",\"dateModified\":\"2026-02-12T14:33:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57014\"},\"wordCount\":415,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Cancer\",\"Niowave\",\"Novartis\",\"NYSE: NVS\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=57014#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57014\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=57014\",\"name\":\"Novartis Secures Long-Term Actinium-225 Supply from Niowave for Radioligand Therapy Expansion - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-02-12T14:33:30+00:00\",\"dateModified\":\"2026-02-12T14:33:32+00:00\",\"description\":\"Novartis AG (NYSE:\u202fNVS) has entered a long-term supply agreement with Niowave Inc., a US-based isotope production company, securing scalable access to Actinium-225 (Ac-225)\u2014a critical alpha-emitting isotope for radioligand therapies (RLT). The deal addresses the severe global supply constraint of Ac-225, enabling Novartis to expand its industry-leading radiopharmaceutical portfolio beyond Lutathera and Pluvicto into next-generation alpha-targeted therapies.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57014#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=57014\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57014#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novartis Secures Long-Term Actinium-225 Supply from Niowave for Radioligand Therapy Expansion\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Novartis Secures Long-Term Actinium-225 Supply from Niowave for Radioligand Therapy Expansion - Insight, China&#039;s Pharmaceutical Industry","description":"Novartis AG (NYSE:\u202fNVS) has entered a long-term supply agreement with Niowave Inc., a US-based isotope production company, securing scalable access to Actinium-225 (Ac-225)\u2014a critical alpha-emitting isotope for radioligand therapies (RLT). The deal addresses the severe global supply constraint of Ac-225, enabling Novartis to expand its industry-leading radiopharmaceutical portfolio beyond Lutathera and Pluvicto into next-generation alpha-targeted therapies.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=57014","og_locale":"en_US","og_type":"article","og_title":"Novartis Secures Long-Term Actinium-225 Supply from Niowave for Radioligand Therapy Expansion","og_description":"Novartis AG (NYSE:\u202fNVS) has entered a long-term supply agreement with Niowave Inc., a US-based isotope production company, securing scalable access to Actinium-225 (Ac-225)\u2014a critical alpha-emitting isotope for radioligand therapies (RLT). The deal addresses the severe global supply constraint of Ac-225, enabling Novartis to expand its industry-leading radiopharmaceutical portfolio beyond Lutathera and Pluvicto into next-generation alpha-targeted therapies.","og_url":"https:\/\/flcube.com\/?p=57014","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-12T14:33:30+00:00","article_modified_time":"2026-02-12T14:33:32+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=57014#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=57014"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Novartis Secures Long-Term Actinium-225 Supply from Niowave for Radioligand Therapy Expansion","datePublished":"2026-02-12T14:33:30+00:00","dateModified":"2026-02-12T14:33:32+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=57014"},"wordCount":415,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Cancer","Niowave","Novartis","NYSE: NVS"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=57014#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=57014","url":"https:\/\/flcube.com\/?p=57014","name":"Novartis Secures Long-Term Actinium-225 Supply from Niowave for Radioligand Therapy Expansion - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-02-12T14:33:30+00:00","dateModified":"2026-02-12T14:33:32+00:00","description":"Novartis AG (NYSE:\u202fNVS) has entered a long-term supply agreement with Niowave Inc., a US-based isotope production company, securing scalable access to Actinium-225 (Ac-225)\u2014a critical alpha-emitting isotope for radioligand therapies (RLT). The deal addresses the severe global supply constraint of Ac-225, enabling Novartis to expand its industry-leading radiopharmaceutical portfolio beyond Lutathera and Pluvicto into next-generation alpha-targeted therapies.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=57014#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=57014"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=57014#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Novartis Secures Long-Term Actinium-225 Supply from Niowave for Radioligand Therapy Expansion"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/57014","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=57014"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/57014\/revisions"}],"predecessor-version":[{"id":57015,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/57014\/revisions\/57015"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=57014"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=57014"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=57014"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}